Ontology highlight
ABSTRACT:
SUBMITTER: Slingluff CL
PROVIDER: S-EPMC3700572 | biostudies-literature | 2013 Jul
REPOSITORIES: biostudies-literature
Slingluff Craig L CL Petroni Gina R GR Molhoek Kerrington R KR Brautigan David L DL Chianese-Bullock Kimberly A KA Shada Amber L AL Smolkin Mark E ME Olson Walter C WC Gaucher Alison A Chase Cheryl Murphy CM Grosh William W WW Weiss Geoffrey R GR Wagenseller Aubrey G AG Olszanski Anthony J AJ Martin Lainie L Shea Sofia M SM Erdag Gulsun G Ram Prahlad P Gershenwald Jeffrey E JE Weber Michael J MJ
Clinical cancer research : an official journal of the American Association for Cancer Research 20130425 13
<h4>Purpose</h4>A CTEP-sponsored phase II trial was conducted to evaluate safety and clinical activity of combination therapy with CCI-779 (temsirolimus) and bevacizumab in patients with advanced melanoma.<h4>Experimental design</h4>Patients with unresectable stage III to IV melanoma were treated intravenously with temsirolimus 25 mg weekly and bevacizumab 10 mg every 2 weeks. Adverse events were recorded using CTCAE v3.0. Tumor response was assessed by Response Evaluation Criteria in Solid Tumo ...[more]